Deep knowledge on
small-molecule drugs and
the 100,000 global patents
covering them

Flexible Flat-Rate Plans

Flat-rate pricing for predictable budgeting

Short-term plans for project- or client-based billing

► Plans and Pricing

How are People Using DrugPatentWatch?

DrugPatentWatch Ultimate Plan Preview

Details for Patent: 5,604,229

« Back to Dashboard
Patent 5,604,229 protects GILENYA and is included in one NDA. There has been one Paragraph IV challenge on Gilenya.

This patent has twelve patent family members in twelve countries.

Summary for Patent: 5,604,229

Title: 2-amino-1,3-propanediol compound and immunosuppressant
Abstract:2-Amino-1,3-propanediol compounds of the formula (I) ##STR1## wherein R is an optionally substituted straight- or branched carbon chain, an optionally substituted aryl, an optionally substituted cycloalkyl or the like, and R.sup.2, R.sup.3, R.sup.4 and R.sup.5 are the same or different and each is a hydrogen, an alkyl, an aralkyl, an acyl or an alkoxycarbonyl, pharmaceutically acceptable salts thereof and immunosuppressants comprising these compounds as active ingredients. The 2-amino-1,3-propanediol compounds of the present invention show immunosuppressive action and are useful for suppressing rejection in organ or bone marrow tranplantation, prevention and treatment of autoimmune diseases or as reagents for use in medicinal and pharmaceutical fields.
Inventor(s): Fujita; Tetsuro (Muko, JP), Sasaki; Shigeo (Kobe, JP), Yoneta; Masahiko (Kobe, JP), Mishina; Tadashi (Iruma, JP), Adachi; Kunitomo (Iruma, JP), Chiba; Kenji (Iruma, JP)
Assignee: Yoshitomi Pharmaceutical Industries, Ltd. (Osaka, JP) Taito Co., Ltd. (Tokyo, JP)
Application Number:08/244,942
Patent Claim Types:
see list of patent claims
Compound; Use;
Patent PDF download available with subscription

Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
CAPSULE;ORAL022527-001Sep 21, 2010RXYes5,604,229<disabled>Y TREATMENT OF AUTOIMMUNE DISEASE
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Foreign Priority and PCT Information for Patent: 5,604,229

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Japan4-283281Oct 21, 1992
Japan5-179427Jul 20, 1993
PCT Information
PCT FiledOctober 18, 1993PCT Application Number:PCT/JP93/01515
PCT Publication Date:April 28, 1994PCT Publication Number: WO94/08943

Non-Orange Book Patents for Patent: 5,604,229

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
5,719,176 2-amino-1,3-propanediol compound and immunosuppressant<disabled in preview>
5,952,316 2-amino-1,3-propanediol compound and immunosuppressant<disabled in preview>
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: 5,604,229

Country Document Number Publication Date Supplementary Protection Certificate SPC Country SPC Expiration
European Patent Office0627406Apr 12, 1995CA 2011 00015Denmark<disabled>
European Patent Office0627406Dec 07, 1994C300488Netherlands<disabled>
Germany122011100012Oct 20, 2011
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plan comparison

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.

Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2016 thinkBiotech LLC
ISSN: 2162-2639

Preferred citation:

Friedman, Y. Location of pharmaceutical innovation: 2000–2009 Nature Reviews Drug Discovery 9, 835–836 (2010).

Connect with Social Media:

Follow DrugPatentWatch on Twitter
Connect with DrugPatentWatch on Linkedin
Drug Patents on LinkedIn